80 related articles for article (PubMed ID: 21059092)
41. Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients.
Cardoso CR; Marques CE; Leite NC; Salles GF
J Hypertens; 2012 May; 30(5):940-7. PubMed ID: 22495135
[TBL] [Abstract][Full Text] [Related]
42. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
43. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.
Shargorodsky M; Wainstein J; Gavish D; Leibovitz E; Matas Z; Zimlichman R
Am J Hypertens; 2003 Aug; 16(8):617-22. PubMed ID: 12878365
[TBL] [Abstract][Full Text] [Related]
44. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo.
Tungsiripat M; El-Bejjani D; Rizk N; Dogra V; O'Riordan MA; Ross AC; Hileman C; Storer N; Harrill D; McComsey GA
AIDS Res Hum Retroviruses; 2011 Mar; 27(3):295-302. PubMed ID: 20969457
[TBL] [Abstract][Full Text] [Related]
45. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study.
Patti AM; Nikolic D; Magan-Fernandez A; Giglio RV; Castellino G; Chianetta R; Citarrella R; Corrado E; Provenzano F; Provenzano V; Montalto G; Rizvi AA; Rizzo M
Diabetes Res Clin Pract; 2019 Mar; 149():163-169. PubMed ID: 30759365
[TBL] [Abstract][Full Text] [Related]
46. Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Gosho M; Shimomura I; Watada H
Sci Rep; 2017 Jan; 7():39965. PubMed ID: 28067320
[TBL] [Abstract][Full Text] [Related]
47. [Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients].
Huang Z; Lei MX; Liu L; Tang QB
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):367-72. PubMed ID: 16859126
[TBL] [Abstract][Full Text] [Related]
48. Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus.
Salahuddin UI; Pandey A; Ayers CR; See R; Neeland IJ; Gore MO; Grinsfelder DB; Abdullah SM; Khera A; de Lemos JA; McGuire DK
Diab Vasc Dis Res; 2016 Mar; 13(2):113-8. PubMed ID: 26701964
[TBL] [Abstract][Full Text] [Related]
49. [Effect of rosiglitazone on level of serum TNF-alpha and its relation with insulin resistance in type 2 diabetes mellitus].
Chen HL; Wu J; Liao L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 29(2):190-1, 211. PubMed ID: 16145910
[TBL] [Abstract][Full Text] [Related]
50. Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.
McGuire DK; Abdullah SM; See R; Snell PG; McGavock J; Szczepaniak LS; Ayers CR; Drazner MH; Khera A; de Lemos JA
Eur Heart J; 2010 Sep; 31(18):2262-70. PubMed ID: 20601395
[TBL] [Abstract][Full Text] [Related]
51. [Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Valensi P
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S35-40. PubMed ID: 12037506
[TBL] [Abstract][Full Text] [Related]
52. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.
Kim MK; Ko SH; Baek KH; Ahn YB; Yoon KH; Kang MI; Lee KW; Song KH
Korean J Intern Med; 2009 Sep; 24(3):227-32. PubMed ID: 19721859
[TBL] [Abstract][Full Text] [Related]
53. The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus.
Svobodová H; Stulc T; Kasalová Z; Doležalová R; Marinov I; Capek P; Ceska R
Physiol Res; 2009; 58(5):701-707. PubMed ID: 19093719
[TBL] [Abstract][Full Text] [Related]
54. Insulin Therapy Is Associated With an Increased Risk of Carotid Plaque in Type 2 Diabetes: A Real-World Study.
Ke JF; Wang JW; Zhang ZH; Chen MY; Lu JX; Li LX
Front Cardiovasc Med; 2021; 8():599545. PubMed ID: 33598483
[No Abstract] [Full Text] [Related]
55. Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial.
Irie Y; Katakami N; Mita T; Takahara M; Matsuoka TA; Gosho M; Watada H; Shimomura I;
Diabetes Ther; 2018 Feb; 9(1):317-329. PubMed ID: 29330812
[TBL] [Abstract][Full Text] [Related]
56. Does rosiglitazone increase cardiovascular outcomes?
Doggrell SA
Expert Opin Pharmacother; 2007 Oct; 8(15):2665-9. PubMed ID: 17931097
[TBL] [Abstract][Full Text] [Related]
57. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
BMJ; 2021 Jun; 373():n1302. PubMed ID: 34078655
[No Abstract] [Full Text] [Related]
58. The rosiglitazone controversy: meta-analysis and the RECORD study.
Liebson PR
Prev Cardiol; 2007; 10(4):235-7. PubMed ID: 17917522
[No Abstract] [Full Text] [Related]
59. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
60. The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
Yee MS; Pavitt DV; Dhanjil S; Godsland IF; Richmond W; Johnston DG
Diabet Med; 2010 Dec; 27(12):1392-400. PubMed ID: 21059092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
